InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.038 -0.002 (-5%)+
Announcement
Release
28 May 2026 9:46AM
Price at Release
$0.040
Full Release
download
Summary
Emyria Limited announced updates from the Therapeutic Goods Administration (TGA) that significantly broaden the recruitment profile for clinicians at its Empax clinics. The updates allow for a wider range of clinicians, including Aboriginal and Torres Strait Islander health workers, to be involved in psychedelic-assisted psychotherapy. These changes aim to diversify the workforce, improve clinic utilization, and enhance patient access to treatments. Emyria is preparing for these changes, which are expected to take effect in the second half of 2026, by updating care models and planning workforce training, awaiting final TGA endorsement.
Key Points
  • TGA updates broaden recruitment profile for Emyria's Empax clinics.
  • Expanded therapist eligibility to include diverse disciplines and support culturally safe care.
  • Expected benefits in clinic utilization, therapist recruitment, and patient access by H2 CY2026.
  • Final endorsement by TGA awaited, with workforce planning and training underway.
  • Positive step reflecting growing evidence and experience with psychedelic-assisted psychotherapy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.